Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Lawrence Howard Schwartz"'
Autor:
Himanshu Nagar, Karla V. Ballman, Scott T. Tagawa, Alan Tan, Bishoy Morris Faltas, Arshin Sheybani, Shiva Baghaie, Lawrence Howard Schwartz, David E. Kozono, Jeffrey A Bogart, Olivia Conway, Gina L. Mazza, Ronald C. Chen, Andrew Leonard Laccetti, Jonathan E. Rosenberg, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 41:TPS589-TPS589
TPS589 Background: In patients (pts) with metastatic unresectable urothelial cancer, platinum-based chemotherapy remains the standard of care for first-line treatment followed by switch maintenance avelumab if disease control is achieved with chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fcb9e603dfb909ce3eed21dd5f8fdae
https://doi.org/10.1200/jco.2023.41.6_suppl.tps589
https://doi.org/10.1200/jco.2023.41.6_suppl.tps589
Autor:
Antonio Tito Fojo, Kevin Brown, Diederik J. Grootendorst, SRIVIDYA KOTAPATI, Matthew Fronheiser, Phuong Tran, Jasmine I. Rizzo, David Leung, Mariann Micsinai Balan, No Firstname Kald.Abdallah@Bms.Com, Binsheng Zhao, Lawrence Howard Schwartz
Publikováno v:
Journal of Clinical Oncology. 40:9063-9063
9063 Background: Tumor growth rates ( g) estimated using imaging measurements, have been associated with overall survival (OS) and progression-free survival (PFS) in patients with mNSCLC, including those treated with first-line immunotherapy (1L IO)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcce24b91c1f20723ea2b6620010f3e9
https://doi.org/10.1200/jco.2022.40.16_suppl.9063
https://doi.org/10.1200/jco.2022.40.16_suppl.9063